DNA X, Inc. (SONM): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of SONM were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No SONM insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SONM short interest
Low short interest. 0.7% of SONM shares are sold short: about 1 share in 151. Over the last 12 reports the number of shares short went down 84%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9,830 SONM shares were sold short, 0.7% of the shares outstanding, down 9.1% from the report before. At the average daily volume of 11,800 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9,830 | 0.66% | -9% | 11,800 | 1.0 |
| Oct 15, 2026 | 10,815 | 0.73% | -38% | 9,016 | 1.2 |
| Sep 30, 2026 | 17,581 | 1.18% | -16% | 31,404 | 1.0 |
| Sep 15, 2026 | 21,039 | 1.41% | +0% | 9,153 | 2.3 |
| Aug 31, 2026 | 21,014 | 1.41% | -19% | 8,828 | 2.4 |
| Aug 14, 2026 | 26,029 | 1.75% | -56% | 17,108 | 1.5 |
| Jul 31, 2026 | 59,407 | 3.99% | +207% | 15,672 | 3.8 |
| Jul 15, 2026 | 19,322 | 1.30% | +21% | 54,856 | 1.0 |
| Jun 30, 2026 | 15,981 | 1.07% | -71% | 18,228 | 1.0 |
| Jun 15, 2026 | 54,245 | 3.64% | -3% | 22,449 | 2.4 |
| May 29, 2026 | 55,934 | 3.76% | -11% | 29,394 | 1.9 |
| May 15, 2026 | 62,760 | 4.22% | -27% | 13,146 | 4.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Dna X company events
Dna X filed 18 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing, auditor). The latest was on Aug 31, 2026.
- Aug 31, 2026AnnouncementDNA X, Inc. received a letter from the Hearings Panel of The Nasdaq Stock Market LLC notifying the Company that the Panel had determined that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain… Filing
- Aug 27, 2026LeadershipThe compensation committee of the board of directors of DNA X, Inc. approved the grant of a cash award (each, a “Substitute Cash Grant”) to all members of the Board, including Mike Mulica, the Company’s Chief Executive Officer, in lieu of a grant of restricted stock units under the Company’s 2019… Filing
- Aug 13, 2026AnnouncementAmended an earlier report. Based on the foregoing transactions, as of the date of the filing of this Current Report on Form 8-K/A, the Company believes it has stockholders’ equity in excess of the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule… Filing
- Jul 9, 2026AnnouncementAmended an earlier report. Based on the foregoing transactions, as of the date of the filing of this Current Report on Form 8-K/A, the Company believes it has stockholders’ equity in excess of the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as reflected in the pro forma… Filing
- Jul 2, 2026AgreementDNA X, Inc. entered into a securities purchase agreement with DNA Holdings Venture, Inc., a holder of more than 5% of the Company’s outstanding capital stock and an entity associated with Scott Walker, a member of the Company’s board of directors, pursuant to which the Company agreed to issue and… Filing
- Jun 4, 2026AgreementEnded an important agreement. Filing
- May 27, 2026ListingAs previously disclosed, on August 22, 2025, the Company received a letter from the staff of the Nasdaq Listing Qualifications Department notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain… Filing
- May 20, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Apr 15, 2026ResultsReleased financial results. Filing
- Mar 2, 2026DealAmended an earlier report. And Item 9.01 to reflect the Company’s determination that the Transaction does not involve the acquisition of a “significant amount of assets” for purposes of Item 2.01 of Form 8-K. Except as expressly set forth herein, this Amendment No. 1 does not amend, modify, or update any other information… Filing
- Feb 10, 2026LeadershipMike Mulica, executive chairman of DNA X, Inc. (formerly, Sonim Technologies, Inc.), a Delaware corporation, was appointed as the Company’s acting chief executive officer and, accordingly, was designated as the Company’s principal executive officer. Filing
- Feb 5, 2026LeadershipPeter Liu, chief executive officer of DNA X, Inc. (formerly, Sonim Technologies, Inc.) a Delaware corporation, notified the Company’s Board of Directors that he was resigning from the office of chief executive officer of the Company and as a director on the Board, effective as of the same date. Filing
- Jan 27, 2026DealThe information contained in the Introduction is hereby incorporated by reference into this Item 2.01. Filing
- Dec 31, 2025VoteReported shareholder vote results. Filing
- Dec 18, 2025DealThe information contained above under the heading “ Note Offering and Purchase of Membership Interest ” in Item 1.01 to the extent applicable is hereby incorporated by reference herein. Filing
- Dec 5, 2025LeadershipThe Compensation Committee of Sonim Technologies, Inc., authorized and approved a contingent cash bonus payable to Clay Crolius, the Company’s Chief Financial Officer. Filing
- Nov 26, 2025AgreementAs previously disclosed on the Current Report on Form 8-K filed by Sonim Technologies, Inc. with the Securities and Exchange Commission on July 22, 2025, the Company entered into that certain asset purchase agreement, dated as of July 17, 2025, by and among the Company, as seller, Pace Car… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dna X financials
Famous investors that hold SONM
1 of the 50 well-known investors we track reported holding SONM in their latest 13F filing. The largest position is Ken Griffin's, worth $81.2K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 17,777 | $81.2K | 0.0% | +40% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SONM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Lawrence W. Lytton | 13G/A | 4.1% |
| Nov 16, 2026 | Lawrence W. Lytton | 13G/A | 4.1% |
Questions about DNA X, Inc. (SONM) stock
Are SONM insiders buying or selling?
No SONM insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in SONM?
As of Oct 30, 2026, 9,830 SONM shares were sold short, 0.7% of the shares outstanding, down 9.1% from the report before. At the average daily volume of 11,800 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold SONM?
1 of the 50 well-known investors we track reported SONM in their latest 13F filing, including Ken Griffin. The largest position is worth $81.2K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.